NASDAQ$AKRO
Akero Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Akero Therapeutics reported third quarter financial results for the period ending September 30, 2020.
Akero Therapeutics reported strongly positive histological data from their FGF21 analog, efruxifermin (EFX), and raised more than $216 million to enable continued development of EFX.
- Reported strongly positive histological data from FGF21 analog, efruxifermin (EFX).
- Raised more than $216 million to enable continued development of EFX.
- Received feedback from the FDA that enables continuation of EFX development with proposed adaptive Phase 2b/3 clinical trial design.
- EFX received PRIME designation from EMA for development as a NASH therapy.
Headline financials
Revenue & EPS history
Akero · Revenue · Quarterly
$0
Forward guidance
Akero is focused on advancing the development of Efruxifermin (EFX) for the treatment of NASH.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
-0.4%
Avg return
Earnings day
-1.8%
Avg return
5 days after
+1.5%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+18.4%
Q2 2022
Best reaction
-20.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.2% | +0.3% | +0.9% | |
| Q2 2025 | +0.1% | -4.2% | -11.3% | |
| Q1 2025 | +4.3% | -2.5% | +33.0% | |
| Q4 2024 | +2.9% | -5.4% | -8.8% | |
| Q3 2024 | -5.2% | -11.2% | -10.8% | |
| Q2 2024 | -3.0% | -4.2% | +6.2% | |
| Q1 2024 | -0.9% | +1.2% | +10.5% | |
| Q4 2023 | +2.1% | +12.0% | -7.3% | |
| Q3 2023 | +5.3% | — | — | |
| Q2 2023 | +6.2% | — | — | |
| Q1 2023 | +0.2% | — | — | |
| Q4 2022 | -4.1% | — | — | |
| Q3 2022 | -6.8% | — | — | |
| Q2 2022 | +18.4% | — | — | |
| Q1 2022 | -11.4% | — | — | |
| Q4 2021 | -1.9% | — | — | |
| Q3 2021 | +4.6% | — | — | |
| Q2 2021 | +1.0% | — | — | |
| Q1 2021 | +2.6% | — | — | |
| Q4 2020 | -1.1% | — | — | |
| Q3 2020 | -3.0% | — | — | |
| Q2 2020 | -0.9% | — | — | |
| Q1 2020 | +2.8% | — | — | |
| Q4 2019 | -20.9% | — | — | |
| Q3 2019 | -3.8% | — | — | |
| Q2 2019 | +1.3% | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro